INSTIL BIO, INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10.4 USD | -2.89% |
|
-0.10% | +36.48% |
| Apr. 15 | North American Morning Briefing : Stock Futures -2- | DJ |
| Apr. 12 | Jefferies Downgrades Instil Bio to Hold From Buy | MT |
Financials (USD)
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 67.64M |
|---|---|---|---|---|---|
| Net income 2024 * | -42M | Net income 2025 * | -68M | EV / Sales 2024 * | - |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-1.64
x | P/E ratio 2025 * |
-1.15
x | Employees | 49 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 93.16% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | -2.89% | ||
| 1 week | -0.10% | ||
| Current month | -3.70% | ||
| 1 month | -6.81% | ||
| 3 months | -11.11% | ||
| 6 months | +36.59% | ||
| Current year | +36.48% |
1 week
10.15
10.78
1 month
10.1511.23
Current year
7.2812.98
1 year
6.0714.00
3 years
6.07473.60
5 years
6.07589.80
10 years
6.07589.80
| Managers | Title | Age | Since |
|---|---|---|---|
Bronson Crouch
CEO | Chief Executive Officer | 51 | 18-10-31 |
Sandeep Laumas
DFI | Director of Finance/CFO | 56 | 20-05-31 |
Mark Dudley
CTO | Chief Tech/Sci/R&D Officer | - | 21-09-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Neil Gibson
BRD | Director/Board Member | 67 | 20-05-31 |
Jack Nielsen
BRD | Director/Board Member | 60 | 20-05-31 |
Richard McGaughy
BRD | Director/Board Member | 52 | 20-05-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.03% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-25 | 10.4 | -2.89% | 21,035 |
| 24-04-24 | 10.71 | -0.37% | 5,112 |
| 24-04-23 | 10.75 | +0.37% | 2,073 |
| 24-04-22 | 10.71 | +0.66% | 6,518 |
| 24-04-19 | 10.64 | +2.21% | 9,899 |
Delayed Quote Nasdaq, April 25, 2024 at 04:30 pm EDT
More quotes
Instil Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies. The Company seeks to in-license/acquire and develop novel therapeutic candidates in diseases with significant unmet medical need. Its first such program is an engineered tumor infiltrating lymphocyte (TIL), cell therapy for the treatment of cancer. It is engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor (CoStAR), platform. The Company's lead CoStAR-TIL product candidate, ITIL-306, expresses a CoStAR molecule designed to recognize folate receptor alpha (Fra), a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC and renal cancer. CAR-T and TCR-T therapies are cell products composed of T cells that have been genetically engineered to recognize a specific cancer-related antigen on the surface of tumor cells.
Calendar
2024-05-08
- Q1 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
10.4
USD
Average target price
27.67
USD
Spread / Average Target
+166.03%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +36.48% | 67.64M | |
| +1.75% | 42.59B | |
| +7.93% | 40.65B | |
| +48.60% | 40.57B | |
| -11.96% | 26.77B | |
| +8.34% | 24.81B | |
| -24.54% | 18.17B | |
| +27.90% | 12.05B | |
| -2.64% | 11.7B | |
| +7.39% | 11.1B |
- Stock Market
- Equities
- TIL Stock
